Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent ...
Recent headlines proclaim a ‘potential’ or ‘functional’ cure for multiple myeloma, but the fight against the disease must ...
We recommend that CTC should be routinely assessed and measured at diagnosis as part of risk evaluation,” study researchers wrote.
In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...
A quote shared during our bi-weekly Tuesday multiple myeloma support group, where five or more gather in the virtual Zoom ...
A combination of genetic tests for a "very complex" blood cancer could accurately predict if the disease is likely to return ...
A study carried out by a team of researchers from The Institute of Cancer Research, London, found that combining two types of ...
The teclistamab-cqyv and daratumumab regimen achieved a 100% overall response rate and MRD negativity in newly diagnosed ...
Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called ...
Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...
The triplet regimen of berdomide, daratumumab (Darzalex), and dexamethasone has led to deepening responses in newly diagnosed, transplant-ineligible patients with multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback